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Abstract
Background: This phase II study investigated efficacy and safety of weekly alternating Bevacizumab (BEV)/
Irinotecan (CPT-11) or Oxaliplatin (OHP) associated to weekly 5-Fluorouracil (5-FU) in first line treatment of
metastatic colorectal carcinoma (MCRC).
Methods: Simon two-step design: delta 20% (p0 50%, p1 70%), power 80%, a 5%, b 20%. Projected objective
responses (ORR): I step, 8/15 patients (pts); II step 26/43 pts. Schedule: weekly 12 h-timed-flat-infusion/5-FU
900 mg/m
2, days 1-2, 8-9, 15-16, 22-23; CPT-11 160 mg/m
2 plus BEV 5 mg/kg, days 1,15; OHP at three dose-levels,
60-70-80 mg/m
2, days 8, 22; every 4 weeks.
Results: Fifty consecutive, unselected pts < 75 years were enrolled: median age 63; young-elderly (yE) 24 (48%);
liver metastases (LM) 33 pts, 66% Achieved OHP recommended dose, 80 mg/m
2. ORR 82% intent-to-treat and 84%
as-treated analysis. Median progression-free survival 12 months. Equivalent efficacy was obtained in yE pts. Liver
metastasectomies were performed in 26% of all pts and in 39% of pts with LM. After a median follow-up of
21 months, median overall survival was 28 months. Cumulative G3-4 toxicities per patient: diarrhea 28%, mucositis
6%, neutropenia 10%, hypertension 2%. They were equivalent in yE pts. Limiting toxicity syndromes (LTS),
consisting of the dose-limiting toxicity, associated or not to G2 or limiting toxicities: 44% overall, 46% in yE.
Multiple versus single site LTS, respectively: overall, 24% versus 20%; yE pts, 37.5% versus 8%.
Conclusion: Poker combination shows high activity and efficacy in first line treatment of MCRC. It increases liver
metastasectomies rate and can be safely administered.
Trial registration: Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del
Farmaco (AIFA) Numero EudraCT 2007-004946-34
Background
Over the last 15 years, multiple active drugs were used
in doublet or triplet combinations of chemotherapy and/
or anti-targets, as first or subsequent lines of treatment
[1-12] and increased overall survival of MCRC pts.
Doublet combinations of 5-FU or Capecitabine asso-
ciated to CPT-11 or OHP or BEV achieve ORR 40%,
progression free survival (PFS) 6-9 months and overall
survival (OS) 15-22 months [1-11]. The addition of BEV
to 5-FU or CPT-11/5-FU/Leucovorin (IFL) significantly
increased, respectively: ORR up to 34.1% and 44.8%; PFS
up to 8.8 and 10.6 months; median OS up to 17.9 and 20.3
months [8-11]. Advantages were also demonstrated with
the addition of BEV to OHP-containing regimens; 5-FU
(bolus plus infusion) or Capecitabine and OHP plus BEV
showed PFS 10 months and OS 26 months [13-16]. Triplet
association of chemotherapy, FOLFOXIRI, also demon-
strated, in a phase III study, a statistically significant
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months, OS 22.6 months [17]. Another phase III study
failed to demonstrate any increase [18]. As the activity of
MCRC treatment progressively increased using triplet
combinations, liver-metastasectomies also raised up to
8-11% of MCRC pts [17,18].
A major problem concerning the addition of more
drugs in a chemotherapy combination is designing a
proper schedule assuring the balance between dose
intensity (DI) of each drug and tolerability. We pre-
viously showed that 12-hour (10
PM to 10
AM)t i m e d - f l a t -
infusion (TFI) of 5-FU associated to CPT-11 can be
safely administered at high 5-FU/DI without Leucovorin;
ORR was 40%, median PFS 10 months, median OS 21
months [19]. The 12-hour (10
PM to 10
AM)T F I / 5 - F U
infusion traces the 12-hour circadian-timed infusion of
5-FU [3,20,21]. Recently, we designed the triplet sche-
dule FIr/FOx by splitting TFI/5-FU weekly with alternat-
ing CPT-11 or OHP: ORR was 66.7%, median PFS was
12 months, median OS 20 months [22].
This present phase II study proposes FIr-B/FOx or
“Poker” association (so called because it represents the
combination of four drugs), adding Bevacizumab to this
triplet chemotherapeutic schedule, in order to assess its
activity, efficacy and safety.
Methods
Patient Eligibility
Pts were eligible if they had histologically confirmed
diagnosis of measurable MCRC; age 18-75 years; World
Health Organization (WHO) performance status ≤ 2;
adequate hematological, renal and hepatic functions; life
expectancy more than 3 months.
Ineligibility criteria: pregnancy and breast-feeding;
uncontrolled severe diseases; cardiovascular disease
(uncontrolled hypertension, uncontrolled arrhythmia,
ischemic cardiac diseases in the last year); thromboem-
bolic disease, coagulopathy, preexisting bleeding dia-
theses; proteinuria > 1 g/24 h urine; surgery within the
previuos 28 days before; previous adjuvant chemotherapy
or radiotherapy completed less than 6 months before.
The study was approved by the Local Ethical Committee
(Comitato Etico, Azienda Sanitaria Locale n.4 L’Aquila,
Regione Abruzzo, Italia) and conducted in accordance
with the Declaration of Helsinki. All patients provided
written, informed consent.
Methods
Schedule
This was a single-arm, multicenter phase II study evalu-
ating activity of weekly alternating 5-FU, CPT-11, BEV
and OHP (FIr-B/FOx) as first-line treatment of MCRC.
FIr-B/FOx or “Poker” association consisted of 5-FU
associated to alternating CPT-11/BEV or l-OHP according
to the following weekly schedule: TFI/5-FU (Fluorouracil
Teva®, Teva), 900 mg/m
2/die, over 12-hour (from 10:00
p.m to 10:00 a.m.), days 1-2, 8-9, 15-16 and 22-23; CPT-
11 (Campto®, Pfizer), 160 mg/m
2,a d m i n i s t e r e do v e r
90 minutes as an intravenous infusion in 250 ml of NaCl
0.9%, days 1 and 15; BEV (Avastin®, Roche), 5 mg/kg,
administered over 90 minutes at the first, 60 minutes at
the second and 30 minutes from the third time, intrave-
nous infusion in 100 ml of NaCl 0.9%, days 1 and 15;
l-OHP (Eloxatin®, Sanofi-Aventis) over 2-hours as an intra-
venous infusion in 250 ml of dextrose 5%, at the dose of
60-70-80 mg/m
2, days 8 and 22. Cycles repeated every
4w e e k s .5 - F Uw a sa d m i n i s t e r e db yap o r t a b l ep u m p
(CADD Plus, SEVIT) using a venous access device.
Study design
Physical examination and routine laboratory studies were
performed at baseline and every week on-treatment,
including complete blood cell count, electrolytes, liver
and renal function tests, urine examination and coagula-
tion function; tumor markers every cycle; electrocardio-
gram every two weeks and echocardiogram at baseline,
and every 3 cycles.
Primary end-point was ORR; secondary end-points
were PFS, toxicity, OS. ORR was evaluated according to
RECIST criteria [23]; PFS and OS using Kaplan and
Meier method [24]. PFS was defined as length of time
between the beginning of treatment and disease progres-
sion or death (resulting from any cause) or to last con-
tact; OS as length of time between the beginning of
treatment and death or to last contact.
Clinical evaluation of response was planned by CT-
scan; PET was added based on investigators’ assessment;
objective responses were confirmed three months later.
Follow-up was scheduled every three months up to dis-
ease progression or death. Toxicity was registered every
week according to National Cancer Institute Common
Toxicity Criteria (NCI-CTC, version 3.0). DLT was
defined as grade 3-4 non-haematological toxicity (mainly
represented by diarrhea, mucositis, neurotoxicity, hand-
foot syndrome, asthenia), grade 4 hematologic toxicity,
febrile neutropenia, or any toxicity determining a > 2
weeks treatment delay.
The concept of limiting toxicity syndromes (LTS),
consisting of at least a dose-limiting toxicity (DLT) asso-
ciated or not to other limiting or G2 toxicities, was
established. These were classified as: LTS in single site
(LTS-ss), if characterized only by the DLT; LTS in mul-
tiple sites (LTS-ms), if characterized by ≥ 2D L T so ra
DLT associated to other, at least G2, non-limiting
toxicities.
Statistical design
This phase II study was planned according to two-steps
Simon’s design [25]: assuming as minimal interesting
activity an ORR 50%, 8 objective responses among the
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Page 2 of 10first 15 enrolled pts were necessary for the first-step; to
verify the alternative hypothesis of ORR 70%, 26 objec-
tive responses among the total 43 pts enrolled were
necessary; power (1 - b) 80%; error probability a 5%. p0
was considered as the activity of triplet combinations in
MCRC (CPT-11/OHP/5-FU or BEV/CPT-11/5-FU)
[17,18,20,11]; p1 as the projected ORR using the present
Poker combination, increasing the activity ≥ 20%.
In the first step of the study, a dose-finding was con-
comitantly developed to verify recommended OHP dose
by 3 escalating steps at 60, 70, 80 mg/m
2, according to
an intra-and inter-patient approach [26].
Results
Patient Demographics
From February 2006 to March 2009, 50 consecutive,
unselected pts were enrolled (Table 1): Male/Female
ratio, 31/19; median age, 63 years; 24 (48%) young-
elderly pts (65 < 75 y); WHO Performance Status 0/1-2,
48/2; metastatic disease metachronous in 15 pts, syn-
chronous in 35 pts. Metastatic sites: liver 33 pts (66%),
lung 10 pts (20%), lymph nodes 17 pts, (34%); local
recurrence 10 pts (20%). Metastatic site was single in 32
pts (64%), multiple in 18 pts (36%). Single metastatic
sites were: liver 22 pts (44%), lung 3 pts (6%), lymph
nodes 3 pts (6%), local recurrence 4 pts (8%). Liver
metastases were single in 11 pts (22%) and multiple in
22 pts (44%).
Dose finding
In the first step of the study, a concomitant dose-finding
was conducted in order to assess the recommended
OHP dose. At the first dose-level, 9 pts were enrolled
and 12 cycles were administered; a DLT, G3 diarrhea,
was observed in 1 out of 9 pts (11%). At the second
dose level, 11 pts were treated (3 new pts); no DLT was
observed. At the third dose level, 14 pts were treated
(3 new pts); a DLT (7%) was observed, characterized by
G3 mucositis (G3 stomatitis and G2 diarrhea, associated
with G2 hypoalbuminemia). Thus, 2 DLTs were
observed out of 15 pts (13%) and out of 37 cycles of
treatment (5%). The OHP dose-finding established that
the maximum tolerated dose (MTD) was not reached at
the third dose level [Additional file 1: Supplemental
Table S1]; thus, the recommended dose of OHP was
80 mg/m
2 day 8 and 22, every 4 weeks.
Activity and efficacy
The preliminary analysis of efficacy, according to the
two-steps Simon’sd e s i g n ,w a sc o n d u c t e da m o n gt h e
first 15 patients: 14 patients were evaluable as treated
and one patient did not received at least three cycles of
treatment. ORR was 93% (a 0.05, CI ± 13) (14 objective
responses): 12 partial responses (80%); 2 complete
responses (13%); 1 progressive disease (7%) [Additional
file 1: Supplemental Table S2].
Overall, 50 pts were enrolled to achieve 43 evaluable pts
(Table 2). In the intent-to-treat analysis 49 pts were evalu-
able (one patient lost to follow-up): ORR was 82% (a 0.05,
CI ± 11). We observed 40 objective responses: 36 partial
responses (73%) and 4 complete responses (CR 8%); 2
Table 1 Patients’ features
Total N. (%)
No. of patients 50
Sex
Male/Female 31/19
Age, years
median 63
range 40-73
≥ 65 years 24 (48)
WHO Performance Status
0 48 (96)
1-2 2 (4)
Metastatic disease
metachronous 15 (30)
synchronous 35 (70)
Primary tumor
colon 24 (48)
rectum 26 (52)
Sites of metastases
liver 33 (66)
lung 10 (20)
lymph nodes 17 (34)
local 10 (20)
Other 5 (10)
No. of involved sites
1 32 (64)
≥ 2 18 (36)
Single metastatic sites
liver 22 (44)
lung 3 (6)
lymph nodes 3 (6)
local 4 (8)
Liver metastases
single 11 (22)
multiple 22 (44)
Previous adjuvant chemotherapy: 9 (18)
FA/5-FU bolus 4 (8)
Capecitabine 1 (2)
FOLFOX4 4 (8)
Previous radiotherapy: 6 (12)
RT alone 2 (4)
RT+CT (5-FU c.i.) 3 (6)
RT+CT (XELOX) 1 (2)
Abbreviation: WHO, World Health Organization; c.i., continous infusion.
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Page 3 of 10stable diseases (4%); 7 progressive diseases (14%). Disease
control rate was 86% (a 0.05, CI ± 10). In the as-treated
analysis, 43 pts were evaluable: 6 pts did not receive at
least three cycles of treatment, due to limiting gastrointest-
inal toxicity (3 patients) requiring treatment discontinua-
tion in 2 of these, surgical resection of liver metastasis
(1 patient) and of local recurrence (1 patient), clinical evi-
dence of progressive disease (1 patient). ORR was 84%
(a 0.05, CI ± 11). We observed 36 objective responses: 32
partial responses (75%) and 4 CR (9%); 2 stable diseases
(5%); 5 progressive diseases (12%). Disease control rate
was 88% (a 0.05, CI ± 10). After a median follow-up of 21
months (Figure 1), median PFS was 12 months (3-46+): 38
events occurred and 12 pts (24%) were progression-free
> 12 months. Median OS was 28 months (3-47): 28 events
occurred and 22 pts (44%) were alive; 80% of pts (40 pts)
were alive > 12 months.
Among the 24 young-elderly pts, in the intent-to-treat
analysis, ORR was 79% (a 0.05, CI ± 12): 16 partial
responses (67%) and 3 CR (12.5%); 5 progressive disease
(21%). In the as-treated analysis, 20 young-elderly pts
were evaluable; ORR was 80% (a 0.05, CI ± 12). After a
median follow-up of 18.5 months, median PFS was 11
months (3-46+): 20 events occurred and 4 pts were pro-
gression-free. Median OS was 20 months (6-46+): 16
events occurred and 8 pts were alive.
Liver metastasectomies were performed in 13 pts of
the 50 enrolled pts (26%); 13 of the 33 pts with liver
metastases (39%) (Table 2). Twelve metastasectomies
out of 22 pts with liver-only metastases (54%) were per-
formed: 6 in 9 pts with single liver metastasis (66%); 6
in 13 pts with multiple liver metastases (46%). In one
patient with single liver metastasis associated with lung
metastases, double metastatic resections were per-
formed. Overall, R0 liver resections were 11 (84.6%), R1
resections were 2 (15.4%). Among the 22 pts with liver-
only metastases, 5 pts had initially resectable disease
(23%), 2 metastasectomies were performed and 2 pts
showed a cCR; 6 pts had initially unresectable disease
(27%), 3 metastasectomies were performed and 1 patient
showed a cCR; 11 pts (50%) had potentially resectable
liver metastases and 7 metastasectomies were per-
formed. No surgery-related complications were reported.
Hepatic steatosis was observed in 3 pts (25%). Liver
metastases showed necrotic areas between 10 and 100%
in 6 pts (50%). In 2 pts with multiple liver-only metas-
tases a pathologic CR was obtained (6% of pts with liver
metastases and 15% of liver metastasectomies).
Overall, 4 clinical and 2 pathologic CRs (12.5%) were
reported; 1 patient showed a progressive disease at 17
months; 5 pts were progression-free at 46, 37, 19, 17
and 12 months, respectively.
Twenty-six pts (52%) received, at least, a second line
treatment: FIr-B/FOx association in 4 pts (8%), who
showed a long-lasting PFS; Cetuximab-containing treat-
ment in 15 pts (30%): Bev-containing in 2 pts (4%); triplet-
chemotherapy (FIr-FOx) in 1 patient (2%); Panitumumab
in 1 patient (2%); Capecitabine alone in 3 pts (6%).
Dose-intensity
Median number of administered cycles was 5 (range
2-9).
Table 2 Activity and efficacy data
Intent-to-treat Analysis As-treated Analysis
No % No %
Enrolled patients 50 100 50 100
Evaluable patients 49 98 43 86
Objective Response 40 82 (CI ± 11) 36 84 (CI ± 11)
Partial Response 36 73 32 75
Complete Response 4 8 4 9
Stable Disease 24 2 5
Progressive Disease 71 4 5 1 2
Median Progression-free survival, months 12
Range 3-46+
Progression events 38 76
Median Overall Survival, months 28
Range 3-47
Deaths 28 56
Liver metastasectomies 13
No/Overall patients (50) 26
No/Patients with liver metastases (33) 39
No/Patients with liver-only metastases (22) 54
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Page 4 of 10Figure 1 Kaplan-Meier survival estimate. (A) Progression-free survival (B) Overall survival. Abbreviation: PFS, progression-free survival; OS,
overall survival.
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were: 5-FU 1487 (480-1800) mg/m
2/w, 82.6% of pro-
jected-DI (pDI); CPT-11 66.7 (25-80) mg/m
2/w, 83% of
pDI; l-OHP 32 (8-40) mg/m
2/w, 80% of pDI; BEV 2.1
(1-2.5) mg/kg/w, 84% of pDI (Table 3). Median rDI
per patient were: 5-FU 1500 (955-1800) mg/m
2/w, 83%
of pDI; CPT-11 66 (45-80) mg/m
2/w, 82.5% of pDI;
l-OHP 32.5 (20.5-40) mg/m
2/w, 81% of pDI; BEV 2
(1.5-2.5) mg/kg/w, 80% of pDI. In young elderly pts,
median rDIs per cycle were: 5-FU 1420 (480-1800)
mg/m
2/w, 80% of pDI; CPT-11 61 (25-80) mg/m
2/w,
76% of pDI; l-OHP 31.5 (8-40) mg/m
2/w, 79% of pDI;
BEV 2 (1-2.5) mg/kg/w, 80% of pDI.
Toxicity
Table 4 describes cumulative toxicities in enrolled pts and
in 247 administered cycles. Two out of 50 patients (4%)
discontinued FIr-B/FOx treatment due to limiting toxicity
(grade 3 diarrhea). Cumulative G3-4 toxicities, by pts,
were: nausea 3 pts (6%), vomiting 2 pts (4%), diarrhea 14
pts (28%), stomatitis/mucositis 3 pts (6%), erythema 1
patient (2%), asthenia 3 pts (6%), hypertension 1 patient
(2%), hypokalemia 1 patient (2%), hypertransaminasemy
2 pts (4%), alopecia 3 pts (6%), neutropenia 5 pts (10%).
The prevalent DLT was diarrhea, equally distributed
among young-elderly and non-elderly pts: 6 pts (25%) and
8 pts (31%), respectively. Other G3-4 toxicities were
mostly observed in the 24 young elderly pts, particularly
nausea 2 pts, vomiting 2 pts, stomatitis/mucositis 3 pts,
erythema 1 patient, asthenia 3 pts, alopecia 3 pts and neu-
tropenia 3 pts. Cumulative G2 toxicities, by pts, were: nau-
sea 15 pts (30%), vomiting 6 pts (12%), diarrhea 12 pts
(24%), hypoalbuminemia 1 patient (2%), stomatitis/muco-
sitis 2 pts (4%), asthenia 20 pts (40%), neurotoxicity 5 pts
(10%), hypertension 4 pts (8%), hematuria 1 patient (2%),
epistaxis 2 pts (4%), hypertransaminasemy 2 pts (4%),
alopecia 9 pts (18%), neutropenia 14 pts (28%), thrombo-
cytopenia 1 patient (2%). No case of thrombosis, hemor-
rhage/bleeding, cardiac or cerebrovascular ischemia, G4
neutropenia, febrile neutropenia, severe thrombocytope-
nia, or toxic deaths were observed.
Overall, LTS were observed in 22 pts (44%) (Table 5);
11 out of 24 young-eldely pts (46%). LTS-ss in 10 pts
(20%); LTS-ms in 12 pts (24%). LTS-ms characterized
by DLT associated to other, at least G2, non-limiting
toxicities were detected in 10 pts (20%); ≥ 2D L T si n2
pts (4%). Among the 24 young-elderly pts the distribu-
tion of LTS was: LTS-ss, 2 pts (8%), LTS-ms, 9 pts
(37.5%). LTS-ms were characterized by: DLT associated
to other, at least G2, non-limiting toxicities, 7 pts (29%);
≥ 2 DLTs, 2 pts (8%). The 10 LTS-ss were characterized
by [Additional file 1: Supplemental Table S3]: G3 diar-
rhea, 5 pts; G3 asthenia, 1 patient; G3 hypertension,
1 patient; G3 hypertransaminasemy, 1 patient; G3 neu-
tropenia, 1 patient; G1 thrombocytopeny for > 2 weeks,
1 patient. The 10 LTS-ms, characterized by DLT asso-
ciated to other, at least G2, non-limiting toxicities, were
characterized by: G3 diarrhea associated with G2-3 nau-
sea and/or G2-3 vomiting, 4 pts; G3 diarrhea associated
with G2 vomiting and G2 neurotoxicity, 1 patient; G3
diarrhea associated with G2 stomatitis/mucositis and G2
asthenia, 1 patient; G3 diarrhea associated with G3 nau-
sea and G2 asthenia, 1 patient; G3 diarrhea associated
with G2 epistaxis, 1 patient; G4 hpertransaminasemy
associated with G2 diarrhea, G2 nausea and G2 anemia,
1 patient; G3 stomatitis/mucositis and G2 asthenia,
1 patient. The 2 LTS-ms, with double DLTs, were
observed in young-elderly pts and characterized by: lim-
iting diarrhea associated with mucositis and mucositis
associated with erythema.
Discussion
The present phase II study proposing FIr-B/FOx asso-
ciation in first line treatment of consecutive, unselected
MCRC pts, reached the primary endpoint: ORR 82% in
the ITT and 84% in the as-treated analysis. After a med-
ian follow-up of 21 months, median PFS was 12 months
and 24% of pts were progression-free > 12 months;
Table 3 Dose-intensity
All patients Young-elderly patients
DI/cycle mg/m
2(or Kg)/w DI/cycle mg/m
2(or Kg)/w
Projected DI mg/m
2(o Kg)/w Median (Range) Received DI (%) Median (Range) Received DI (%)
5-FU 1800 1487 82,6 1420 80
(480-1800) (480-1800)
CPT-11 80 66.7 83 61 76
(25-80) (25-80)
l-OHP 40 32 80 31.5 79
(8-40) (8-40)
BEV 2.5 2.1 84 2 80
(1-2.5) (1-2.5)
Abbreviation: DI, dose-intensity; 5-FU, 5-Fluorouracil; CPT-11, Irinotecan; l-OHP, Oxaliplatin; BEV, Bevacizumab.
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alive > 12 months.
The subsequent generations of randomized studies
[8,10,11,13,14,17,18] showed increased activity and effi-
cacy starting from ORR ≤ 20%, PFS 5 months and OS
≤ 14 months of 5-FU alone. Doublets consisting of
CPT-11, or OHP, or BEV associated to 5-FU or Capeci-
tabine gained ORR 20.0-47.0%, PFS 5.9-9.0 months and
OS 15.1-21.5 months, without demonstrating differences
between 5-FU/BEV associations compared to 5-FU or
Capecitabine with CPT-11 or OHP. Triplets consisting
of chemotherapeutic drugs or doublets plus BEV
obtained ORR 39.0-66.0%, PFS 8.3-10.6 months and OS
20.3-26.1 months. In particular, the addition of a third
drug, either BEV or OHP, equivalently increased the
efficacy of doublet combination associating 5FU/CPT-
11; 5-FU or Capecitabine and OHP plus BEV shows OS
20.4-26.1 months [13,14]. Based on these data, a phase
II study of four drug association, adding BEV to FOL-
FOXIRI, was recently proposed [27].
We previously showed that doublet and triplet che-
motherapy using TFI/5-FU, without Leucovorin, accord-
ing to the present schedule [19,20], obtained equivalent
Table 4 Cumulative toxicity
Patients Cycles
Number 50 247
NCI-CTC Grade 1 2 3 4 1 2 3 4
Nausea (%) 23 (46) 15 (30) 3 (6) - 81 (33) 23 (9) 4 (2) -
Vomiting (%) 10 (20) 6 (12) 2 (4) - 19 (8) 9 (4) 2 (1) -
Diarrhea (%) 20 (40) 12(24) 14 (28) - 76 (30) 28 (11) 15 (6) -
Hypoalbuminemia (%) 2 (4) 1 (2) - - 2 (1) 1 (0.5) - -
Constipation (%) 17 (34) 1 (2) - - 22 (9) 1 (0.5) - -
Stomatitis/mucositis (%) 16 (32) 2 (4) 3 (6) - 29 (12) 3 (1) 3 (1) -
Erythema (%) 1 (2) - 1 (2) - 3 (1) - 1 (0.5) -
Asthenia (%) 13 (26) 20 (40) 3 (6) - 48 (19) 38 (15) 3 (1) -
Neurotoxicity (%) 36(72) 5 (10) - - 126(51) 6 (2) - -
Hypertension (%) 15 (30) 4 (8) 1 (2) - 27 (11) 4 (2) 1 (0.5) -
Hypotension (%) 1 (2) - - - 1 (0.5) - - -
Hematuria (%) 2 (4) 1 (2) - - 3 (1) 1 (0.5) - -
Gengival recession/gengivitis (%) 7 (14) - - - 10 (4) - - -
Rhinitis (%) 38 (76) - - - 110(44.5) - - -
Epistaxis (%) 31 (62) 2 (4) - - 68 (27.5) 2 (1) - -
HFS (%) 2 (4) - - - 2 (1) - - -
Headache (%) 6 (12) - - - 9 (4) - - -
Hypokalemia (%) 3 (6) - 1 (2) - 3 (1) - 1 (0.5) -
Hypertransaminasemy (%) 3 (6) 2 (4) 1 (2) 1 (2) 9 (4) 6 (2) 1 (0.5) 1 (0.5)
Hyperpigmentation (%) 6 (12) 2 (4) - - 14 (6) 5 (2) - -
Fever without infection (%) 10 (20) - - - 10 (4) - - -
Alopecia (%) 5 (10) 9 (18) 3 (6) - 11 (4) 17 (7) 7 (3) -
Anemia (%) 7 (14) 4 (8) - - 16 (6) 4 (2) - -
Leucopenia (%) 13 (26) 17 (34) - - 49 (20) 26 (10.5) - -
Neutropenia (%) 9 (18) 14 (28) 5 (10) - 35 (14) 32 (13) 8 (3) -
Thrombocytopenia (%) 7 (14) 1 (2) - - 16 (6) 1 (0.5) - -
Abbreviation: NCI-CTC, National Cancer Institute Common Toxicity Criteria.
Table 5 Limiting Toxicity Syndromes (LTS): overall and in
young-elderly patients
Overall Young-elderly
N. % N. %
Patients 50 100 24 100
Limiting Toxicity Syndromes (LTS) 22 44 11 46
LTS single-site (LTS-ss) 10 20 2 8
LTS multiple-sites (LTS-ms) 12 24 9 37.5
Single DLT plus G2-3 10 20 7 29
Double DLTs 2 4 2 8
Abbreviation: DLT, dose-limiting toxicity; G, grade.
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Page 7 of 10efficacy to other reported schedules (ORR 40% and
66.7%, PFS 10 and 12 months, OS 21 and 20 months,
respectively) and demonstrated a good tolerability pro-
file [19,20,28]. In this scenario, Poker combination, add-
ing BEV to FIr-FOx association, in first line treatment
of MCRC, increased activity compared to triplet associa-
tions and it also increased efficacy; the 48% young
elderly pts enrolled showed equivalent activity and
efficacy.
Randomized studies of doublets (5-FU plus CPT-11 or
OHP) adding Cetuximab (an EGFR-inhibitor) in EGFR-
overexpressing pts, showed equivalent efficacy to other
triplet combinations [29,30]; in these studies, k-ras wild-
type status was reported as a statistically relevant predic-
tive biomarker of higher activity and efficacy. Preliminary
data of a phase III trial may also confirm this with Pani-
tumumab plus FOLFOX4 [31]. The effectiveness of BEV-
containing treatments was maintained in k-ras wild-type
as it was in k-ras mutated pts [32].
Liver metastasectomies were performed in 26% of
MCRC pts and 39% of pts with liver metastases. Moreover,
54% of pts with liver-only metastases and 50% of pts with
initially unresectable liver metastases underwent surgical
resection. Liver metastasectomies were reported in 8-11%
of pts treated with triplet chemotherapy (36% in liver-only
pts) [17,18] and in 7.6% of pts in BEV-containing associa-
tions (15.2% in liver-only pts) [16]; in pts with potentially
curable liver metastases, they were 92.8% [15]. In Cetuxi-
mab-containing associations [29,30], metastasectomies
were performed in 7% and 4.7% of overall pts [29,30]; 9.8%
of KRAS wt pts [30]. More, using neoadjuvant Cetuximab
with either FOLFOX6 or FOLFIRI for unresectable color-
ectal liver metastases, metastasectomies were performed in
38% and 30% of pts, respectively [33]. Our data show that
more active first line treatment of MCRC [34], such as
Poker combination, contribute to increase efficacy also by
raising surgical resection of liver metastases.
Median rDIs per cycle and per patient were > 80% for
each drug; in young elderly pts, only the rDI of CPT-11
was lower than 80% (76%; 61 mg/m
2/w). Cumulative
G3-4 toxicities were prevalently represented by diarrhea
(28%), stomatitis/mucositis (6%), asthenia (6%), hyperten-
sion (2%), hypertransaminasemy (4%), neutropenia (10%).
Cumulative G3-4 toxicities reported with the schedule
associating BEV to 5-FU/Leucovorin or IFL were repre-
sented by equivalent prevalence of, respectively: diarrhea
28.5% and 32.4%; hypertension 8.5% and 11%; thrombotic
events 14.2% and 19.4% [8,11]. Cumulative G3-4 toxici-
ties reported with FOLFOXIRI schedules [17,18] were
prevalently represented by, respectively: diarrhea 20%
and 27.7%, stomatitis/mucositis 5% and 5%, asthenia 6%
and 5.6%, neutropenia 50% and 35%, febrile neutropenia
5% and 7%, neurotoxicity 2% and 5.8%. Thus, gastroin-
testinal toxicities were not quite different in patients
treated with 5-FU and CPT-11 as doublet, or associated
to BEV, or OHP, or BEV and OHP as in the present
study. Preliminary safety data of the phase III trial evalu-
ating BEV plus FOLFOXIRI versus BEV plus FOLFIRI,
show cumulative G3-4 toxicities prevalently represented
by diarrhea (18%), stomatitis/mucositis (8%), asthenia
(4%), hypertension (2%), trombotic events (8%), neutro-
penia (53%), febrile neutropenia (6%); a treatment-related
death was reported in 1 patient (gastrointestinal bleeding;
2%). Thus, FIr-B/FOx schedule determined only 10% G3-
4 neutropenia, while FOLFOXIRI schedule, added or not
to BEV [35,17], prevalently induced it (53% and 50%,
respectively) and also febrile neutropenia (6% and 5%,
respectively).
Cumulative G3-4 toxicities in young-elderly pts were
prevalently represented by diarrhea (25%), hypertransa-
minasemy (4%), neutropenia 12.5%, stomatitis/mucositis
(12.5%), asthenia (12.5%). Souglakos et al reported a sig-
nificantly higher incidence of G3-4 diarrhea in elderly
versus non-elderly pts either in the FOLFIRI or in the
FOLFOXIRI arm [18]. In our study, DLT was observed
in 44% of pts and in 46% of young-elderly pts, with no
differences of cumulative G3-4 toxicities by pts and by
cycles. The innovative clinical evaluation of LTS, con-
sisting of at least the DLT associated or not to other
G2 or limiting toxicities, was introduced to better evalu-
ate, in the individual patient, the presence of DLT
alone, LTS-ss, or the association of major toxicities in
different sites, LTS-ms: overall, they were 20% and 24%
respectively; among young-elderly pts, they were 8% and
37.5%, respectively. Most LTS-ms (2 double DLTs and
7 out of 10 DLT associated to other, at least G2, non-
limiting toxicities) were observed in this subgroup. LTS-
ms were mostly represented by diarrhea and/or stomati-
tis/mucositis associated to nausea, vomiting and/or
asthenia.
Conclusions
Randomized trials will confirm if intensive chemother-
apy approaches, such as Poker association, increase effi-
cacy, also by raising surgical resection of liver
metastases, as first line treatment of MCRC. The present
schedule is feasible, also in young-elderly pts, with man-
ageable toxicity. Young-elderly pts show equivalent effi-
cacy and cumulative toxicity, with a prevalence of LTS-
ms associating the DLT with other moderate/severe
toxicities.
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